SER-109 Improves Quality of Life Compared to Placebo in Patients with Recurrent Clostridioides difficile Infection
A secondary analysis of a Phase III clinical trial found SER-109 improved health-related quality of life for patients with recurrent C. difficile infection compared to placebo through eight weeks.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.